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A B S T R A C T
Background
Acute kidney injury (AKI) is common in patients undergoing cardiac surgery among whom it is associated with poor outcomes,
prolonged hospital stays and increased mortality. Statin drugs can produce more than one effect independent of their lipid lowering
effect, and may improve kidney injury through inhibition of postoperative inflammatory responses.
Objectives
This review aimed to look at the evidence supporting the benefits of perioperative statins for AKI prevention in hospitalised adults after
surgery who require cardiac bypass. The main objectives were to 1) determine whether use of statins was associated with preventing
AKI development; 2) determine whether use of statins was associated with reductions in in-hospital mortality; 3) determine whether
use of statins was associated with reduced need for RRT; and 4) determine any adverse effects associated with the use of statins.
Search methods
We searched the Cochrane Renal Group’s Specialised Register to 13 January 2015 through contact with the Trials’ Search Co-ordinator
using search terms relevant to this review.
Selection criteria
Randomised controlled trials (RCTs) that compared administration of statin therapy with placebo or standard clinical care in adult
patients undergoing surgery requiring cardiopulmonary bypass and reporting AKI, serum creatinine (SCr) or need for renal replacement
therapy (RRT) as an outcome were eligible for inclusion. All forms and dosages of statins in conjunction with any duration of pre-
operative therapy were considered for inclusion in this review.
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Data collection and analysis
All authors extracted data independently and assessments were cross-checked by a second author. Likewise, assessment of study risk
of bias was initially conducted by one author and then by a second author to ensure accuracy. Disagreements were arbitrated among
authors until consensus was reached. Authors from two of the included studies provided additional data surrounding post-operative
SCr as well as need for RRT. Meta-analyses were used to assess the outcomes of AKI, SCr and mortality rate. Data for the outcomes of
RRT and adverse effects were not pooled. Adverse effects taken into account were those reported by the authors of included studies.
Main results
We included seven studies (662 participants) in this review. All except one study was assessed as being at high risk of bias. Three studies
assessed atorvastatin, three assessed simvastatin and one investigated rosuvastatin. All studies collected data during the immediate
perioperative period only; data collection to hospital discharge and postoperative biochemical data collection ranged from 24 hours to
7 days. Overall, pre-operative statin treatment was not associated with a reduction in postoperative AKI, need for RRT, or mortality.
Only two studies (195 participants) reported postoperative SCr level. In those studies, patients allocated to receive statins had lower
postoperative SCr concentrations compared with those allocated to no drug treatment/placebo (MD 21.2 µmol/L, 95% CI -31.1 to
-11.1). Adverse effects were adequately reported in only one study; no difference was found between the statin group compared to
placebo.
Authors’ conclusions
Analysis of currently available data did not suggest that preoperative statin use is associated with decreased incidence of AKI in adults
after surgery who required cardiac bypass. Although a significant reduction in SCr was seen postoperatively in people treated with
statins, this result was driven by results from a single study, where SCr was considered as a secondary outcome. The results of the meta-
analysis should be interpreted with caution; few studies were included in subgroup analyses, and significant differences in methodology
exist among the included studies. Large high quality RCTs are required to establish the safety and efficacy of statins to prevent AKI
after cardiac surgery.
P L A I N L A N G U A G E S U M M A R Y
Do statins prevent kidney failure in adults after surgery where cardiac bypass is used?
Heart surgeries are performed routinely in developed countries and their safety has increased significantly. However, heart surgery is still
associated with complications. Of those, kidney failure is of great importance; and patients whose kidneys fail after a heart operation
are more likely to have other health problems. Preventing kidney failure after heart surgery is therefore a major health issue.
Cardiac bypass, which replaces heart and lung functions by diverting blood from major vessels to a machine during surgery, is required
for most major heart operations. Cardiac bypass is known to release molecules that cause inflammation into the blood. In susceptible
people, these molecules could cause kidney failure. Statins are drugs used to decrease fatty acid (lipid) levels in the blood and help
prevent cardiac and vascular disease. Statins also seem to decrease the general level of inflammation in the blood. Although animal
studies have suggested that statins could help to prevent kidney failure after heart surgery, they can also cause adverse effects. More
evidence is required before statins can be routinely used.
This review aims to evaluate evidence on the use of statins at the time of heart surgery to investigate if use can help to prevent kidney
failure and how well statins are tolerated among patients. We searched the literature to January 2015 and included seven studies that
involved a total of 662 participants to inform our assessment. In these studies, patients planned for heart surgery received statins or
placebo (or no treatment at all). Five studies (467 participants) reported rates of kidney failure. We found that there was a high risk of
bias in six of the seven included studies.
We found no difference in the rate of kidney failure between patients who received statins and those who did not. Two studies (195
patients) reported serum creatinine (a marker of kidney function) after the operation. We found that serum creatinine was lower
in patients in the statin group (indicating better kidney function). Other conclusions were limited by the small number of studies.
However, patients who received statins did not seem to need less dialysis. They did not have a higher rate of death in hospital and did
not have an increased rate of adverse events.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Statin therapy compared with placebo for reduction in AKI after cardiac surgery with bypass
Patient or population: adults undergoing surgery requiring cardiac bypass
Settings: hospital inpatients
Intervention: statin treatment prior to cardiac bypass surgery
Comparison: placebo or no drug therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no drug ther-
apy
Statins
Acute kidney injury
Follow-up: ICU stay
27/232 (11.6%) 21/235 (8.9%) RR 0.76 (0.46 to 1.28) 467 (5) ⊕⊕©©
low
No significant difference.
High risk of bias in most
studies
Serum creatinine
Follow-up: first 72 h post-
operative
The mean serum creati-
nine ranged across con-
trol groups from 77.6 to
106 µmol/L
The mean serum cre-
atinine in intervention
groups was on average
21 µmol/L lower
(95% CI -31.09 to -11.
41)
195 (2) ⊕⊕©©
low
Significant differ-
ence, both studies have
high risk of bias
Renal replacement ther-
apy
Follow-up: ICU stay
5/124 (4.0%) 4/127 (3.1%) RR 0.8 (0.23 to 2.81) 251 (2) ⊕©©©
very low
No significant difference.
Only one study reported
the need for renal replace-
ment therapy
Mortality
Follow-up: hospital stay
0/189 (0%) 3/192 (1.6%) RR 3.86 (0.43 to 34.4) 381 (5) ⊕©©©
very low
No significant difference.
Very low event rate. High
risk of bias amongst stud-
ies
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Adverse events
Follow-up: treatment du-
ration
8/70 (11.4%) 9/70 (12.9%) RR 1.13 (1.47 to 2.68) 140 (1) ⊕©©©
very low
No significant difference.
Only one study ade-
quately reported adverse
events
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
ICU - intensive care unit
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B A C K G R O U N D
Description of the condition
AKI is a common complication of cardiac surgery; incidence
ranges from 1% to 30% according to the definition used (Conlon
1999; Mariscalco 2011; Ostermann 2000; Thakar 2003). Car-
diac surgery-associated AKI (csa-AKI) has been shown to be in-
dependently associated with increased morbidity and mortality
(Chertow 1997) and a more complicated course of hospital ad-
mission. AKI is associated with longer intensive care unit (ICU)
stays and increased costs, especially when renal replacement ther-
apy (RRT) is required (Coca 2009; Srisawat 2010; Swaminathan
2007).
Cardiopulmonary bypass use has been identified as an important
risk factor for occurrence of csa-AKI (Bove 2004; Chawla 2012;
Lamy 2012), and morbidity and mortality has not changed over
the last decade despite significant advances in bypass technology
(Swaminathan 2007). Other risk factors for development of AKI
post cardiopulmonary bypass include pre-existing chronic kidney
disease (CKD) (Chertow 1997), older age (Mangano 1998), fe-
male gender (Asimakopoulos 2005), reduced left ventricular func-
tion (Mistiaen 2009), congestive heart failure (Mangano 1998),
diabetes mellitus (Chukwuemeka 2005), peripheral vascular dis-
ease (Chukwuemeka 2005), pre-operative use of an intra-aortic
balloon pump (Bove 2004), need for emergent surgery (Bove
2004), pre-existing anaemia (Karkouti 2009), cardiopulmonary
bypass time (Bove 2004), duration of cross clamp time (Mistiaen
2009) and requirement for vasopressor support (Arora 2008).
Although an overall decrease in renal blood flow has been shown
to significantly contribute to the diminished glomerular filtration
rate (GFR) observed in ischaemic kidney injury, decreased renal
blood flow alone cannot account for the total reduction in GFR.
Renal toxicity is also thought to be mediated by cardiopulmonary
bypass triggered activation of bone marrow derived cells, endothe-
lial cells and renal epithelial cells resulting in reactive oxygen species
generation and release of inflammatory mediators (Boyle 1997).
The adhesion of inflammatory cells to activated endothelium in
peritubular capillaries of the outermedulla leads tomedullary con-
gestion and hypoxic injury to the proximal tubule. Pro-inflamma-
tory cytokines secreted by infiltrating and resident cells contribute
to further tissue injury until inflammatory resolution and tubular
epithelial proliferation occurs bringing a return to normal tissue
function (Devarajan 2006).
Description of the intervention
Statins competitively inhibit the enzyme 3-hydroxy 3-methylglu-
taryl CoA (HMGCoA) reductase which catalyses the rate limiting
step in cholesterol synthesis (Endo 1976). Since approval for clin-
ical use in 1987 statins have been shown to reduce the progression
of atherosclerosis, improve survival and reduce the risks of vascular
death, non-fatal myocardial infarction, stroke, and the need for
coronary revascularisation across a wide range of cholesterol levels
(Baigent 2005).
How the intervention might work
In addition to their lipid lowering actions, statins have been shown
to exert anti-inflammatory and pleiotropic effects (Haslinger-
Löffler 2008). In experimental models of AKI (Gueler 2002;
Inman 2005; Yokota 2003), statins have been shown to preserve
kidney function. Similarly, Mariscalco 2011 suggested that statins
could reduce postoperative leukocyte and endothelial activation
and result in significantly lower postoperative pro-inflammatory
serum cytokine levels.
There is some evidence that statin administration before percuta-
neous coronary interventions reduces periprocedural cardiovascu-
lar events. However, results are inconsistent when AKI (contrast-
induced nephropathy) was considered as an outcome (Jo 2008;
Ozan 2010; Patti 2008). A recent meta-analysis (Li 2012) sup-
ported the use of statins to prevent contrast-induced nephropathy
but concluded that their use must be considered in the context
of variable patient demographics. Although the pathophysiology
of contrast-induced nephropathy is not fully understood, inflam-
mation and oxidative stress may play an important role similar
to a postulated mechanism of kidney injury after cardiac bypass
surgery. Only small RCTs have been published to date, and results
among patients undergoing cardiac surgery are conflicting.
Why it is important to do this review
Current evidence consists of numerous observational studies and
a few small RCTs. Large observational studies have generated con-
flicting results: some suggest that statin administration could be as-
sociated with lower csa-AKI incidence (Billings 2010; Clark 2006;
Tabata 2007) but others have suggested no effect (Ali 2005; Pan
2004). Given their retrospective nature, such studies are limited
by selection bias and their conclusions must be considered with
care. Several systematic reviews have evaluated the overall bene-
fits of perioperative statins in cardiac surgery (Liakopoulos 2008;
Liakopoulos 2012); however, none have focused on AKI as a pri-
mary outcome.
There is a considerable need for effective therapies that prevent
AKI in this setting because kidney dysfunction after surgery re-
sults in significantly increased morbidity compared with patients
who maintain normal kidney function (Karkouti 2009). In gen-
eral, prevention of kidney reperfusion injury after cardiac by-
pass surgery involves correction of dehydration and minimising
nephrotoxins. Therefore, evidence indicating that statins help to
prevent kidney injury in this setting will help to address this thera-
peutic gap. Recent evidence (including among patients not requir-
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ing RRT following AKI) suggests that kidney injury is associated
with increased long-term mortality risk independent of residual
kidney function, with risk proportionate to the severity of the kid-
ney injury (Lafrance 2010).
This review focused on AKI and procedures requiring cardiac by-
pass, except cardiac transplantation surgery and correction of con-
genital cardiac defects. All levels of kidney injury were included.
O B J E C T I V E S
This review aimed to look at the evidence supporting the benefits
of perioperative statins for AKI prevention in hospitalised adults
after surgerywho require cardiac bypass. Themain objectiveswere:
1. To determine whether use of statins was associated with
preventing AKI development
2. To determine whether use of statins was associated with
reductions in in-hospital mortality
3. To determine whether use of statins was associated with
reduced need for RRT
4. To determine any adverse effects associated with the use of
statins.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published RCTs that compared statin use with placebo or stan-
dard treatment givenpreoperatively to patients undergoing surgery
who required cardiac bypass were eligible for inclusion. The dose,
type or duration of statins used was not restricted. Case reports
and non-randomised studies were not eligible for inclusion.
Types of participants
Inclusion criteria
All adult patients (aged > 18 years) undergoing surgery requiring
cardiopulmonary bypasswere included. Studies including children
or mixed child and adult populations were excluded unless data
were presented separately. Studies that included patients undergo-
ing cardiac surgery who did not require cardiopulmonary bypass
were excluded.
Exclusion criteria
1. Patients on extracorporeal RRT before the initiation of the
study
2. Patients undergoing cardiac transplantation or corrective
surgery for congenital heart disease
3. Kidney transplant recipients.
Types of interventions
We considered studies that investigated the use of statin therapy
for any given duration and dose prior to surgery in people re-
quiring cardiac bypass compared with placebo, no drug therapy
or standard clinical care. All statins were considered for inclusion,
with a priori subgroup analysis defined.
Types of outcome measures
Primary outcomes
The primary outcome is the incidence of AKI after cardiac surgery.
AKI is defined using the AKIN or RIFLE classification wher-
ever provided. The Acute Kidney Injury Network (AKIN) (Mehta
2007) defines three stages of injury (1, 2 and 3) based on increas-
ingly severe reductions of kidney function (Stage 1: increase in
serum creatinine (SCr) ≥ 0.3 mg/dL, or 1.5- to 2-fold increase
from baseline; Stage 2: increase in SCr ≥ 150% to 200% from
baseline; Stage 3: increase in SCr > 3-fold from baseline, > 300%
from baseline, ≥ 4.0 mg/dL, or initiation of RRT regardless of
stage). The RIFLE criteria, proposed by the Acute Dialysis Quality
Initiative group (Bellomo 2004) defines five levels of AKI (Risk,
Injury, Failure, Loss and End-stage kidney disease) based on in-
cremental reductions in kidney function.
If AKI was not reported in the context of these criteria, efforts
were made to classify patients.
Secondary outcomes
1. SCr changes during the same hospitalisation
2. In-hospital mortality
3. Need for RRT during the same hospitalisation
4. Adverse effects attributed to the intervention (elevated liver
enzymes, creatinine kinase levels, rhabdomyolysis or drug
withdrawal).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Renal Group’s Specialised Register to
13 January 2015 through contact with the Trials’ Search Co-or-
dinator using search terms relevant to this review. The Cochrane
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Renal Group’s SpecialisedRegister contains studies identified from
the following sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the
proceedings of major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of the Cochrane Renal Group. Details of these strate-
gies, as well as a list of handsearched journals, conference proceed-
ings and current awareness alerts, are available in the Specialised
Register section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
Further potential studies were assessed through handsearching ref-
erence lists of nephrology textbooks, review articles and relevant
studies. Letters were submitted seeking information about unpub-
lished or incomplete studies to investigators known to be involved
in previous studies.
Data collection and analysis
Selection of studies
Literature search was performed using the predefined search strat-
egy (Appendix 1) to identify studies eligible for inclusion. The
titles and abstracts were screened initially. Studies that poten-
tially contained information relevant to the review were retained,
whereas studies that did not meet the pre-specified criteria were
excluded. All potentially relevant studies were then uploaded to
a reference management database. Each author independently re-
viewed the abstract or full text (where required) of the retained
articles to assess suitability for inclusion in this review. Reasons for
exclusion were noted. Cross checking was performed by at least
one further author to determine the final eligibility for inclusion,
and disagreements were arbitrated amongst all three authors until
a consensus was reached.
Data extraction and management
Data were extracted independently by all three authors using a
standardised data extraction form, which was designed by AS and
initially piloted by all three authors. The information obtained
from each included study was cross-checked by at least one ad-
ditional author. Disagreements were arbitrated between all three
authors until a consensus was reached.Wheremore than one pub-
lication of a study existed, reports were grouped together and the
most complete data set was included. Any discrepancy between
published versions has been highlighted. Unclear data were clari-
fied through correspondence with the study authors and any data
obtained in this way were included in the review and analysis. Data
extracted included study design, inclusion and exclusion criteria,
patient numbers and characteristics. Treatment regimen and dura-
tion as well as duration of follow-up were included. For outcomes
of interest (AKI, SCr, mortality, need for RRT, adverse events), the
raw data were extracted using mean, median and standard devi-
ations for continuous outcomes, and event rate for dichotomous
outcomes.Where datawere collected atmore than one time-point,
we extracted all data and analysed different time-points for com-
parison.
Assessment of risk of bias in included studies
All three authors independently performed the risk of bias assess-
ment for between two to three of the included studies, with each
assessment cross-checked by a second author. Any disagreements
were arbitrated between all three authors until a consensus was
reached.Risk of biaswas assessed using a risk of bias assessment tool
(see Appendix 2), and according to the standards of the Cochrane
Collaboration (Higgins 2011). The following items were assessed.
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?
◦ Participants and personnel
◦ Outcome assessors
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
In each domain, studies were labelled as low, high or unclear risk
of bias with consideration given to the presence or absence of suf-
ficient information to make a determination. Reasons for assess-
ment were documented (See Characteristics of included studies),
and a risk of bias summary is presented.
Measures of treatment effect
For dichotomous outcomes (e.g. proportion of AKI, need for RRT,
mortality rates and number of adverse events), results are expressed
as risk ratios (RR) with 95% confidence intervals (CI), calculated
using the random effects model. A RR < 1 favours statin treatment
over control. As postoperative SCr is a continuous outcome it was
first converted to standardised units (µmol/L) and themean differ-
ence (MD) with 95% CI was subsequently used for comparisons.
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Unit of analysis issues
Studies with non-standard designs, such as cross-over studies and
cluster-randomised studies were not included in this review.
Dealing with missing data
Any missing outcome data were requested from the correspond-
ing author of the study. All the relevant information obtained via
this method was included in this review. In one included study
(Almansob 2012), there was lack of information surrounding SCr
levels which were graphically presented. After written correspon-
dence, the authors of this study provided mean and standard de-
viation of the SCr level and blood urea nitrogen (BUN) preoper-
atively, and at 24 hours, 48 hours and 72 hours postoperatively.
Data surrounding need for RRT and mortality data were also pro-
vided. An author from Prowle 2012 was contacted for periopera-
tive SCr data, which were also provided. No further missing out-
come data were imputed for the purposes of this review. Given the
universally short follow-up periods of the included studies, loss
to follow-up was minimal. In one study that reported 15 patients
dropped out (Prowle 2012), data within this study were analysed
on intention-to-treat principle, followed by reanalysis on per-pro-
tocol basis, in which no outcomes were materially affected. The
intention-to-treat data from this study were used for the purposes
of this review. In the only other study reporting significant drop
outs (Almansob 2012), only those completing the study were in-
cluded in the analysis, and study data were used as reported.
Assessment of heterogeneity
We assessed the heterogeneity between included studies using the
Chi2 test on N-1 degrees of freedom with an alpha of 0.05 used
for statistical significance and with the I2 statistic (Higgins 2003).
We considered statistical significance in heterogeneity surround-
ing calculation of the I2, although Chi2 with alpha < 0.05 was also
considered. Based on the Cochrane Handbook (Higgins 2011), I
2 of 0% to 40% may not be important, I2 of 30% to 60% may
represent moderate heterogeneity, I2 of 50% to 90% may repre-
sent substantial heterogeneity and I2 of 75% to 100% may repre-
sent considerable heterogeneity. Visual inspection of forest plots
provided added evidence of heterogeneity.
Assessment of reporting biases
In order to detect any publication bias, electronic searching of web
sites with current clinical study protocols was undertaken. Funnel
plot analysis (Sterne 2001) was planned to further investigate,
however there were insufficient number of included studies and
this analysis was not feasible.We also assessed selective reporting of
outcomes in the included studies. Language bias wasminimized by
not applying any language restrictions during the search strategy.
Data synthesis
The data from the available studies were pooled using the ran-
dom effects model (DerSimonian 1986), however the fixed effects
model (Egger 1997) was also undertaken for comparison. The
random effects model was used for the primary analysis as there is
variability in the form, dose and duration of statin therapy used
amongst studies of this nature, and some heterogeneity was ex-
pected. Before a pooled data analysis was performed for each out-
come of interest, we assessed all the relevant studies to determine
the eligibility of data comparison. We excluded pooled data anal-
ysis and only presented the result with narrative description when
there were not sufficient comparable data available for a specific
outcome.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was used to explore possible sources of hetero-
geneity such as those amongst participants, treatments and study
quality. Heterogeneity in patients could be related to age, preop-
erative renal pathology and other risk factors for renal reperfu-
sion injury. Heterogeneity in treatments could be related to prior
agent(s) used and the dose, duration and type of statin used. De-
spite small numbers of included studies, we investigated the po-
tential differences through subgroup analysis according to type of
statin used.
Sensitivity analysis
We planned to perform sensitivity analyses if there were sufficient
studies identified, in order to explore the influence of the following
factors on effect size.
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias, as
specified above
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country.
Too few studies were identified that met the inclusion criteria for
this review, therefore sensitivity analyses were not undertaken.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies
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Results of the search
We identified 89 records from the Cochrane Renal Group’s
Specialised Register (Figure 1); no studies were identified from
searches of the reference lists of relevant review articles (
Liakopoulos 2008; Morgan 2009). After screening titles, abstracts
and the full text, 53 studies (71 records) were excluded and two
ongoing studies were identified (NCT01547455; STATIN AKI
2011). Seven studies met our inclusion criteria (Almansob 2012;
Chello 2006; Christenson 1999; Mannacio 2008; Prowle 2012;
Tamayo 2009; Spadaccio 2010).
Figure 1. Study flow diagram.
Prior to publication of this review a final search of the Specialised
Register identified five new potential studies and these will be
assessed for inclusion in a future update of this review (de Oliveira
2012; Han 2013; Liu 2013; NAPLES II Study 2009; ROSA-cIN
Trial 2013).
Included studies
The seven studies included in our analyses were all RCTs and
included a treatment arm of statin and comparator arm of no drug
treatment or placebo. The studies included had variable primary
outcomes, however all included at least one of the pre-specified
outcomes of interest for this review. Authors were contacted to
provide data for SCr and urine output and additional information
for SCr was gained from two of the included studies.
See Characteristics of included studies
Design
After evaluation, seven RCTs published between 1999 and 2012
were included in this review. All were published in English.
Sample size
Sample size varied from40 (Christenson 1999) to 200 participants
(Mannacio 2008) to provide data on a total of 662 adult patients
undergoing cardiac surgery, of whom 334 received statin therapy
and 328 received placebo or no drug therapy.
Setting
Five of the seven studies were undertaken in European centres, and
one each in China and Australia. All were undertaken in inpatient
hospital settings with follow-up limited to inpatient hospital stays.
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Participants
All studies evaluated adult inpatients undergoing cardiac bypass.
One study exclusively enrolled patients undergoing non-coronary
artery surgery (Almansob 2012) compared to the other included
studies that predominantly evaluated those undergoing coronary
artery bypass surgery. Most studies excluded those with baseline
kidney impairment (Chello 2006; Mannacio 2008; Prowle 2012;
Spadaccio 2010; Tamayo 2009) although of note, there was no
consensus amongst these studies on levels of kidney impairment
that led to exclusion.
Interventions
Three studies evaluated atorvastatin (Prowle 2012; Spadaccio
2010; Chello 2006), three evaluated simvastatin (Almansob 2012;
Christenson 1999; Tamayo 2009) and one study evaluated ro-
suvastatin (Mannacio 2008). All studies compared pre-operative
statin treatment to placebo or no drug treatment. Use of statins
prior to enrolment was variable, with three studies (Almansob
2012;Christenson 1999 Tamayo 2009) not reporting prior use.
Two studies (Chello 2006; Spadaccio 2010) had amandated statin-
free period of more than one year prior to enrolment, and two
studies had much shorter statin-free periods of a minimum 30
days (Mannacio 2008) and 24 hours (Prowle 2012) prior to en-
rolment.
Doses of statin used varied; atorvastatin ranged from 20 mg/d
(Chello 2006; Spadaccio 2010) to 40mg/d (Prowle 2012), simvas-
tatin was 20 mg/d (Almansob 2012; Christenson 1999; Tamayo
2009) and rosuvastatin was 20 mg/d (Mannacio 2008). Of note,
only Christenson 1999 titrated statin dose to lipid levels, with sim-
vastatin increased to 40 mg two weeks prior to surgery if adequate
lipid lowering had not been achieved.
Duration of preoperative statin therapy was also variable between
the studies, with periods ranging from commencement on the
day of operation (Prowle 2012) through to four weeks preopera-
tively (Christenson 1999). Three of the studies commenced ther-
apy three weeks prior to surgery (Chello 2006; Spadaccio 2010;
Tamayo 2009) and two studies commenced therapy between
five to seven days preoperatively (Almansob 2012; Mannacio
2008). The period of postoperative statin therapy was not clar-
ified in 5/7 studies (Chello 2006; Christenson 1999; Mannacio
2008; Spadaccio 2010; Tamayo 2009). In two studies the statin
was continued for three days postoperatively (Prowle 2012) and
recommenced on day two postoperatively for ongoing therapy
(Almansob 2012).
Outcomes
With the exception of Prowle 2012 none of the studies listed
AKI as a primary outcome. For our pre-specified outcomes of
interest, 5/7 studies reported AKI (Chello 2006; Prowle 2012;
Christenson 1999; Spadaccio 2010; Mannacio 2008), 3/7 studies
reported SCr (Almansob 2012; Prowle 2012; Tamayo 2009), 2/7
studies reported need for RRT (Almansob 2012; Prowle 2012), 5/
7 reported mortality (Almansob 2012; Chello 2006;Prowle 2012;
Spadaccio 2010; Tamayo 2009), and 2/7 studies reported adverse
events (Chello 2006; Prowle 2012). Standardisation of outcome
reporting for the outcomes of AKI, SCr and adverse events was
a significant issue. The definitions of AKI ranged from using the
validated RIFLE criteria (Prowle 2012), to using a single SCr cut-
off (Christenson 1999) or increase in SCr (Mannacio 2008) to
providing no clarifying definition (Chello 2006; Spadaccio 2010).
No conversion to AKIN criteria was able to be achieved. Units of
measure of SCrwere able to be freely converted toµmol/L, however
time point reporting varied widely amongst studies. Almansob
2012 reported SCr data at 24, 48 and 72 hour time points, while
for Tamayo 2009 the time-point of SCr was unable to be clarified,
although data collection was ceased at 48 hours. Prowle 2012
reported only peak SCr values, which were taken one to five days
postoperatively. Finally, adverse events were defined clearly in one
study (Prowle 2012) as alanine transferase (ALT) > 3 times the
upper limit or normal (ULN), creatine kinase (CK) > 5000 IU/L,
or study drug being stopped by the treating clinician. Chello 2006
reported only that no adverse events were experienced, without
qualification.
Excluded studies
Overall, 53 studies were excluded after critical appraisal of title,
abstract or full text (See Characteristics of excluded studies). One
study didnot fulfil the criteria for aRCT; 24 containednooutcome
of interest, 25 were excluded as they did not use cardiac bypass in
the procedure and three did not use statins as a comparator arm,
or used a statin in both arms.
Risk of bias in included studies
See Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Overall, the study quality was variable, with high risk of bias as-
sessed in at least one domain for 5/7 studies (Almansob 2012;
Mannacio 2008; Christenson 1999; Spadaccio 2010; Tamayo
2009). Only Prowle 2012 was considered truly to be at low risk
of bias, with Chello 2006 assessed as unclear risk of bias based on
identification of potential selection bias.
Allocation
Only three of the studies were assessed as low risk, with adequate
description of randomisation methods including the use of com-
puter generated algorithms (Almansob 2012; Mannacio 2008;
Prowle 2012). The other four studies (Chello 2006; Christenson
1999; Spadaccio 2010; Tamayo 2009) made variable mention of
randomisation, however they did not provide enough detailed in-
formation regarding actual randomisation procedures undertaken
to determine risk of bias, and were therefore deemed to be unclear.
Blinding
Whilst the mention of ’blinding’ was made in the majority of
studies, the methods by which this was achieved were not clearly
described. Only two of the studies mademention of use of placebo
and the methods undertaken to administer this (Mannacio 2008;
Prowle 2012). Despite this, the outcome measures of interest for
this review (AKI, need for RRT, SCr,mortality and adverse events)
are objective, and thus it was felt that whilst this represented poor
reporting practices for the majority of the studies it did in fact
constitute a low risk of bias for these outcome measures.
Incomplete outcome data
Most studies reported no loss to follow-up or incomplete outcome
data. This is likely secondary to the short follow-up period, with
no long-term follow-up undertaken in any study. Two studies re-
ported patient drop out, with incomplete data collection. One
study (Prowle 2012) reported a number of patient drop-outs (15),
however study results were not affected when reanalysed on a per
protocol basis, with the primary analysis remaining as intention
to treat. The missing data were evenly spread across groups (statin
(8); control (7)) and dropout was for comparable reasons. Given
this transparency, it was felt that this represented low risk of bias.
The second study (Almansob 2012) reported that 19 patients were
excluded from the analysis (statin (9), placebo (10)). The drop
out was for comparable reasons, including liver dysfunction (statin
(2), placebo (3)), and non-completion not further defined (statin
(4), placebo (6)). A further two patients in the statin group under-
went surgery without cardiac bypass. Whilst these patients were
excluded from the analysis, the dropout is even across groups and
for comparable reasons, so again, was felt to represent low risk of
bias.
Selective reporting
All the studies reported the outcomes that were prespecified in
their methods. However, 5/7 studies were felt to have high risk
of reporting bias (Almansob 2012; Christenson 1999; Mannacio
2008; Spadaccio 2010; Tamayo 2009) as drug studies would be
expected to report adverse events as outcome data and these studies
failed to do so. Prowle 2012 very clearly reported definitions of
adverse events and event rate. Chello 2006 did report that no
adverse drug related events were seen, however failed to define
what constituted an event. As such, this was determined to be
unclear risk of bias as judgement was unable to be made.
Other potential sources of bias
Christenson 1999 was industry funded, however made no men-
tion of the role that this funding body played in the design and
execution of the study or analysis of results, therefore risk of bias
was deemed high. Two studies did not reporting funding and were
deemed unclear (Mannacio 2008; Spadaccio 2010). No other po-
tential sources of bias were identified.
Effects of interventions
See: Summary of findings for the main comparison
See Summary of findings for the main comparison. Seven studies
enrolling 662 participants were evaluated. Both fixed and random
effects models were used in the initial analysis. No significant dif-
ferences were found, therefore the summary estimates reported
here were from the random effectsmodels. Given the limited num-
ber of included studies, no sensitivity analysis was undertaken.
Postoperative AKI
Five studies (467 participants) reported postoperative AKI (
Chello 2006; Prowle 2012; Christenson 1999; Spadaccio 2010;
Mannacio 2008). There was no significant difference between
groups in preventing postoperative AKI (Analysis 1.1 (5 studies,
467 participants): RR 0.76, 95% CI 0.46 to 1.28). There was
no significant heterogeneity demonstrated (I2 = 0%). Despite the
limited number of studies, a subgroup analysis by statin class was
performed. For those studies using atorvastatin no statistically sig-
nificant difference was seen in postoperative AKI between groups
(Analysis 1.1.1 (3 studies, 190 participants): RR 0.83, 95% CI
0.46 to 1.49). For the single studies assessing simvastatin and ro-
suvastatin, no differences were seen between the groups (Analysis
1.1.2; Analysis 1.1.3). Subclass differences were assessed, with a
calculated I2 of 34%, indicating a potential low level of variabil-
ity amongst studies when considering result by statin subgroup.
Whilst this may indicate different effects by statin (i.e. trends to
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benefit versus harm by class used), the low event rates overall and
wide confidence intervals seen in conjunction with the low num-
ber of studies in each subgroup make it difficult to draw firm con-
clusions.
Postoperative serum creatinine
Three studies (195 participants) reported postoperative SCr
(Almansob 2012; Prowle 2012; Tamayo 2009). Given differences
in outcome reporting previously described, pooled analysis was
only possible for two of these studies (Almansob 2012; Tamayo
2009 (195 participants). Statin treatment significantly decreased
24 hour postoperative SCr (Analysis 1.2 (2 studies, 195 partici-
pants): MD -21.25 µmol/L, 95% CI -31.09 to -11.41; I2 = 0%)
with the result driven by differences seen in one study (Almansob
2012) which received 85.7% of the weighting. As data were avail-
able at two time points for this study, analysis of the 48 hour SCr
was also significantly decreased in the statin group (Analysis 1.3
(2 studies, 195 participants): MD -20.97µmol/L, 95% CI -34.58
to -7.35; I2 = 12%). Given that Tamayo 2009) collected data to
a maximum of 48 hours, the 72 hour time point was not under-
taken.
Perioperative mortality
Mortality outcomes were reported in six studies (458 participants)
(Almansob 2012; Chello 2006; Christenson 1999; Prowle 2012;
Spadaccio 2010; Tamayo 2009). Given the universally short peri-
ods of follow-up, low numbers of deaths were reported, all within
the statin treatment arm of two studies (Almansob 2012; Tamayo
2009). Despite the individual studies showing trends to favour
placebo for this outcome, there was no statistically significant dif-
ference in mortality seen between groups in the pooled analysis
(Analysis 1.4 (6 studies, 458 participants): RR 3.86, 95% CI 0.43
to 34.40). There was no significant heterogeneity (I2 = 0%) seen.
With low event rates demonstrated confidence intervals were ex-
tremely wide, again making any interpretation of these results dif-
ficult.
Need for postoperative renal replacement therapy
Need for postoperative RRT was reported in two studies (
Almansob 2012; Prowle 2012). Almansob 2012 reported no need
for RRT in either group and there were near equal numbers need-
ing RRT reported in Prowle 2012. There was no statistically sig-
nificant difference between statin treatment and placebo (Analysis
1.5 (2 studies, 251 participants): RR 0.80, 95% CI 0.23 to 2.81).
There was no significant heterogeneity demonstrated (I2 = 0%)
Adverse events
Two studies (140 participants) reported adverse events however
one study (Chello 2006) did not report adverse events related to
statin use therefore no pooled analysis was undertaken. Prowle
2012 reported rise in ALT x 3 upper limit of normal, creatine
kinase rise > 5000 IU/L and study drug cessation, the compared
event rate between the groups did not reach statistical significance
(P = 0.36, 0.36 and 1.0 respectively).
Prowle 2012 reported adverse events related to statin use. There
was no significant difference in rise in ALT x 3 upper limit of
normal (Analysis 1.6.1 (100 participants): RR 0.25, 95% CI 0.03
to 2.16), rise in creatine kinase > 5000 IU/L (Analysis 1.6.2 (100
participants): RR 4.00, 95% CI 0.46 to 34.54) or study drug
cessation (Analysis 1.6.3 (100 participants): RR 1.33, 95% CI
0.31 to 5.65) between atorvastatin and placebo.
D I S C U S S I O N
Summary of main results
After a search of the literature, seven RCTs with a total of 662
participants that addressed the use of statin intervention prior to
cardiac bypass surgery and its effects on perioperative kidney in-
jury were identified. All the included studies assessed our prespec-
ified primary outcome of AKI, or one of our secondary outcomes
of SCr, need for RRT or adverse events, although with the ex-
ception of one (Prowle 2012), all kidney outcomes were consid-
ered as secondary within the original studies. Three studies as-
sessed atorvastatin (Chello 2006; Prowle 2012; Spadaccio 2010;
190 participants), three studies assessed simvastatin (Almansob
2012; Christenson 1999; Tamayo 2009; 272 participants) and one
study used rosuvastatin (Mannacio 2008; 200 participants), with
high variability in drug washout period (24 hours (Prowle 2012)
to more than one year (Chello 2006; Spadaccio 2010)). Duration
of pre-operative drug therapy ranged from treatment commenc-
ing on the operative day (Prowle 2012) to four weeks preoper-
atively (Christenson 1999). All studies were assessed as having a
high risk of bias, with the exception of Prowle 2012 which was
assessed as having a low risk of bias in all five assessed domains.
Study follow-up was uniformly short, with all the studies collect-
ing data to hospital discharge, and biochemical data collection
ranging from 24 hours postoperatively (Spadaccio 2010) up to
seven days (Almansob 2012; Christenson 1999).
Overall for the outcome of AKI, the studies were variable in their
results, however no individual study showed significant differences
between statin treated and non-drug treated groups. Our resultant
meta-analysis therefore showed no significant difference between
the statin and comparator arms for incidence of AKI postopera-
tively (RR 0.76, 95% CI 0.46 to 1.28) (See Summary of findings
for the main comparison). The only finding of significance from
all outcomes assessed was the difference in postoperative SCr be-
tween statin and placebo groups, an outcome which was measured
in three studies (Almansob 2012; Prowle 2012; Tamayo 2009).
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Of these, significant variability in time-point measurements al-
lowed only two of the studies to be pooled for analysis. The third
study (Prowle 2012) showed no significant difference in maxi-
mal SCr reached between postoperative days 1 to 5 between the
statin and placebo arms (rise of 28 µmol/L (16 to 55) versus
29 (16 to 54), P = 0.62). In the meta-analysis (Almansob 2012;
Tamayo 2009), the group treated with statin showed a mean post-
operative SCr of 21.25 µmol/L lower than the non-drug treated
group (95% CI -31.09 to -11.41, P < 0.0001). This result was
largely driven through the strongly positive results in one study
(Almansob 2012), where SCr data at 24, 48 and 72 hour time-
points showed a significant benefit of statin therapy over no drug
treatment (24 hour (MD -23.30 µmol/L, 95% CI -33.93 to -
12.67, P < 0.0001). For all other assessed outcomes (need for
RRT, mortality, adverse events) no statistically or clinically signif-
icant difference was found between statin therapy and placebo or
no therapy. Reliable conclusions were not able to be drawn from
these analyses given the low numbers of studies reporting these
outcomes, and concomitant low event rates.
Overall completeness and applicability of
evidence
There are significant limitations to this review. Given the lack of
large, high-quality RCTs, our meta-analysis was limited to small
heterogeneous studies. Studies were conducted in a range of set-
tings, from Europe to China and Australia, with potentially im-
portant socio-demographic and procedural differences between
the centres. Similarly, despite recruiting populations of adult pa-
tients undergoing cardiac bypass, the included studies had dif-
ferent protocols and preoperative treatment duration, with inclu-
sions ranging from exclusively statin naive patients (Christenson
1999) to accepting different periods of drug washout, a setting un-
likely to be seen in current clinical practice. For all studies but one
(Prowle 2012), the statin was administered before the operative
day, but the pre-operative treatment duration ranged from seven
days (Almansob 2012) to four weeks (Christenson 1999). In ad-
dition, different statins were used as part of these protocols. Three
studies used atorvastatin (Chello 2006; Prowle 2012; Spadaccio
2010), three used simvastatin (Almansob 2012,Christenson 1999;
Tamayo 2009) andMannacio 2008 used rosuvastatin. To take into
account this potential for different effects across drug formulation,
subgroup analyses were performed.However given the small num-
ber of patients, the power to detect a difference is very limited.
The outcomes of interest for this review were largely secondary
outcomes within the included studies, and therefore lack of con-
sensus definition for AKI was an issue. Two studies (Christenson
1999; Mannacio 2008) used SCr cut-offs to dichotomise patients
into AKI or no AKI (125 µmol/L for the first and 221µmol/L for
the latter), while Prowle 2012 used the currently recommended
RIFLE criteria (Bellomo 2004), which are based both on a ratio
of peak over baseline SCr level and urinary outputs. Finally, two
studies (Chello 2006; Spadaccio 2010) did not report their defi-
nition for AKI.
Overall, only minimal information about post-operative kidney
function was available in these reports as AKI was only a secondary
outcome in all but one study (Prowle 2012). The event numbers
were low for many outcomes, and therefore power to detect differ-
ences between the groups may be limited. The safety of statin use
in surgery requiring cardiac bypass was unable to be assessed as a
secondary outcome due to a lack of reported data in the majority
of included studies.
Quality of the evidence
With the exception of Prowle 2012, all of the studies were assessed
as having high risk of bias in at least one domain. Drug studies
would be expected to report clearly on the presence or absence
of adverse events related to drug administration, however only
Prowle 2012 adequately assessed and reported these events. In ad-
dition, most studies stated that randomisation was undertaken,
without describing the methods of randomisation, allocation con-
cealment and blinding of study participants. In cases where blind-
ing was stated to have occurred, several studies did not describe
use of a placebo, raising significant questions as to how blinding
could possibly have been adequate. Despite this, outcome mea-
sures in this case were objective and therefore most studies were
assessed as low risk of bias in this domain. Authors of the included
studies were therefore not contacted to further clarify randomisa-
tion strategies. Compliance to newly prescribed medication may
well be poor, which would potentially significantly affect the out-
comes of the included studies. None of the included studies mea-
sured or addressed the issue of compliance directly, although one
(Christenson 1999) did measure serial lipid profiles to assess pre-
operative change in the setting of statin use. Overall, given that
6/7 included studies had identified high risk of bias in at least
one domain in addition to significant differences in methodol-
ogy and outcome reporting practices, the quality of the evidence
was assessed as low or very low across all outcome measures (See
Summary of findings for the main comparison).
Potential biases in the review process
We believe that all relevant studies were identified. A thorough
search strategy was devised and all major databases were searched
for relevant studies, with no language restrictions applied. All three
authors assessed the studies for inclusion in the review and the risk
of bias, with discrepancy discussed between the three authors. The
biggest limitation of the review process was that not all studies
reported the outcome of interest or reported in a different fash-
ion. This is related to the lack of thoroughly accepted definition
for AKI. Despite attempting to obtain additional data, we were
not able to obtain sufficient data to adequately classify all patients
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according to the RIFLE (Bellomo 2004) or AKIN (Mehta 2007)
classification, and therefore our primary outcome (AKI) was con-
sidered as a dichotomous outcome rather than a stratified outcome
based on reporting in the included studies. We did not include
the results of unpublished studies. Studies with both positive and
negative results were identified, making the possibility of publica-
tion bias less likely. No sensitivity analysis was able to be under-
taken given the small number of studies eligible for inclusion in
this review.
Agreements and disagreements with other
studies or reviews
To our knowledge, this is the first completed review that assesses
the impact of preoperative statin use for surgery requiring cardiac
bypass on the incidence of postoperative AKI.However, there have
been systematic reviews that examined multiple clinical outcomes
with the use of preoperative statin therapy after cardiac surgery. A
systematic reviewwithmeta-analysis (Liakopoulos 2008) included
more than 30,000 participants. It was shown that statin therapy
had no effect on postoperative kidney failure (OR 0.78, 95% CI
0.46 to 1.31). This was in agreement with our findings. However,
it reported an incidence of 4.1% kidney failure in a total of 6408
patients. This was much lower than our incidence of 10.3% AKI
out of total of 467 patients. The discrepancy could be due to the
fact that the majority of studies included in Liakopoulos 2008
were retrospective observational studies (only two small RCTs out
of five studies), whereas this review included five RCTs for this
particular analysis. There was also significant heterogeneity ob-
served in Liakopoulos 2008 (P = 0.05; I2 = 58.3%).
In a more recent Cochrane review performed by the same author
(Liakopoulos 2012), four studies reported the incidence of kidney
failure in a total of 367 participants. The incidence of kidney fail-
ure was 3.2% in the statin group compared to 7.1% in the control
group. This Cochrane analysis showed that statin treatment did
not lead to a significant reduction of the odds of kidney failure
(OR 0.41, 95% CI 0.15 to 1.12; P = 0,08). Our analysis also did
not show any statistically significant difference between the two
groups (RR 0.76; 95% CI: 0.46 to 1.28). A significant difference
between our analysis and the previous Cochrane review related to
inclusion in this review of a recent RCT reporting the outcome
of AKI (Prowle 2012). It was a well-designed study with low risk
of bias and it carried an important weight in the pooled analysis.
In Prowle 2012, there were 13/50 patients with AKI in the statin
group compared to 16/50 in the placebo group, (RR 0.81, 95%
CI 0.44 to 1.51). This result would have likely attenuated the sta-
tistical trend observed in Liakopoulos 2008.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When considering the five RCTs (467 participants) that reported
the primary outcome of AKI, our analysis demonstrated no reduc-
tion in AKI incidence in the setting of preoperative statin therapy.
Whilst postoperative SCr was significantly lower in those treated
with statins preoperatively (compared to placebo), only two stud-
ies (195 participants) adequately reported this outcome and results
were driven by the results of a single study. As such, there is signif-
icant uncertainty regarding the strength of this result, and we are
unable to draw a definitive conclusion. Overall, no reduction in
mortality or need for RRT was seen with statin treatment. Adverse
events were poorly reported in most studies, and no significant
differences seen in the only study that reported this outcome ade-
quately. Overall, there was no evidence of improved kidney health
outcomes or mortality associated with empirical statin therapy for
adults undergoing surgery requiring cardiac bypass.
Implications for research
Although our analysis did not show any benefit of preoperative
statin therapy in the reduction of AKI for cardiopulmonary by-
pass surgery, our conclusion was drawn from only small number
of studies with limited number of patients in total. Most of the
studies were designed to investigate the incidence of AKI as a sec-
ondary outcome. Moreover, the outcome definition varied among
different studies. Therefore further larger studies with their main
focus on perioperative kidney function are required in order to
investigate any potential effect of preoperative statin therapy. It is
also necessary for future studies to have a standardised definition
of AKI, such as the AKINor RIFLE consensus classification which
would allow more meaningful comparisons to be made.
Further research is also required to assess any potential benefit
of different types of statin therapy and different dose regimens.
As there are newer statin agents emerging in the market, more
studies are required to explore any potential renoprotective benefit
of such agents. Upcoming studies should also collect detailed data
regarding adverse events associated with statin use, as this was
lacking in most of the RCTs included in this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Almansob 2012
Methods • Study design: parallel RCT
• Study duration: September 2010 to June 2011
Participants • Setting: single inpatient centre
• Country: China
• Health status: elective non-coronary artery surgery; baseline CKD not reported
◦ DM: treatment group (4); control group (2)
◦ Hypertension: treatment group (9); control group (6)
◦ Chronic statin use: not reported
◦ Emergency surgery: treatment group (0); control group (0)
• Number: treatment group (77); control group (74)
• Mean age ± SD (years): treatment group (45.5 ± 14.5); control group (41.5 ± 18.
7)
• Sex (M/F): treatment group (30/47); control group (35/39)
• Exclusion criteria: coronary artery disease; contraindications to statin treatment;
aged < 10 years; gestating or lactating women
Interventions Treatment group
• Simvastatin
◦ Dose, duration, frequency, administration: 20 mg for 5 to 7 days pre-
operatively (not on day of surgery; recommenced day 2 postoperatively
• Routine medications
Control group
• Routine medications
• Dose, duration, frequency, administration: not reported
Outcomes • Mortality
• SCr (µmol/L): mean (SD) measured preoperatively and 24, 48 and 72 h
postoperatively
• RRT
Notes • Supported by: Sun Yat-Sen University Clinical Research Program, National
Science Foundation of China, Ministry of Education for China, various other
government departments
• Authors of this study provided mean and standard deviation of the SCr level and
blood urea nitrogen (BUN) preoperatively, and at 24 hours, 48 hours and 72 hours
postoperatively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation used
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Almansob 2012 (Continued)
Allocation concealment (selection bias) Unclear risk Information not provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “... patients, surgeons, anaesthetists, perfu-
sionists, ultrasound physicians, individuals
collecting the samples... were all blinded”
Blindingmethods for the control groupnot
reported. However, this was unlikely to in-
fluence outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “...people performing the data analysiswere
all blinded”
Nocomment onhow thiswas achieved, but
given objective outcome measures, consid-
ered low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow diagram: 9 patients from statin arm
and 10 from placebo arm were excluded
from the analysis: 4 statin and 6 placebo
arm participants did not complete the
study, 2 statin and 3 placebo arm partici-
pants had liver dysfunctionpostoperatively,
2 statin arm participants did not undergo
bypass. 68 participants in statin arm and
64 in placebo arm underwent analysis
Despite there being evidence of missing
data, this was assessed as low risk of bias,
because missing data were balanced across
groups for similar reasons and therefore was
unlikely to have a clinically relevant impact
Selective reporting (reporting bias) High risk All prespecified outcomes were reported.
Comment: We would expect a drug study
to clearly describe the outcome of drug and
non-drug related adverse events which did
not occur here, thus this is deemed high
risk
Other bias Low risk No other risk of bias was identified
Chello 2006
Methods • Study design: parallel double blinded, placebo controlled RCT
• Study duration: May 2003 to September 2004
Participants • Setting: single centre, inpatient
• Country: Italy
• Relevant health status: patients scheduled to undergo CABG
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Chello 2006 (Continued)
◦ Hypertension: treatment group (10); control group (8)
• Number: treatment group (20); control group (20)
• Mean age ± SD (years): treatment group (65.7 ± 7.7); control group (63.7 ± 7.1)
• Sex: (M/F): treatment group (16/4); control group (15/5)
• Exclusion criteria: DM; kidney or liver impairment; CHF; active inflammatory or
immunomodulatory diseases; history of MI < 6 months; pregnant women
Interventions Treatment group
• Atorvastatin
• Dose, duration, frequency, administration: 20 mg/d; 3 weeks before surgery
Control group
• Placebo
• Dose, duration, frequency, administration: 3 weeks before surgery
Outcomes • Number with AKI: “renal insufficiency” not defined
• Mortality
Notes • “This study was supported by Sun Yat-sen University Clinical Research 5010
Program; the National Natural Science Foundation of China (30971261 and
81170271); Ministry of Education of China (20100171110057); The Science and
Technology Research for the Returned Overseas Chinese Scholars from Ministry of
Human Resources and Social Security of China (2011); and Bureau of Science and
Information Technology of Guangzhou, China (2010GN-E00221).”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects fulfilling inclusion criteria were
randomised”.
Randomisation method details not speci-
fied
Allocation concealment (selection bias) Unclear risk Information not provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both patients and physicians were blinded
to the drug assignment group”
Placebo was not described so it is unclear
how this was possible. However, the out-
comes of interest were objective and there-
fore unlikely to be affected
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Information not provided. This was as-
sessed as low risk because the outcomes of
interest were objective and therefore un-
likely to be affected
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence or reporting of dropouts
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Chello 2006 (Continued)
Selective reporting (reporting bias) Unclear risk “All patients randomised to atorvastatin
treatment did not experience any side effect
related to the drug”
The definition of adverse events was not
given, nor was this a prespecified secondary
outcome, therefore we deem this unclear
risk of bias as clear judgement is unable to
be made
Other bias Low risk No other risk of bias was identified for this
study
Christenson 1999
Methods • Study design: parallel RCT
• Study duration: November 1997 to April 1998
Participants • Setting: Single centre, inpatient
• Country: Switzerland
• Relevant health status: hypercholesterolaemic adults with coronary disease
undergoing CABG
◦ Baseline CKD: not reported
◦ DM: treatment group (9); control group (9)
◦ Hypertension: treatment group (19); control group (20)
◦ Chronic statin use: not reported
◦ Emergency surgery: treatment group (34); control group (33)
• Number: treatment group (40); control group (37)
• Mean age ± SD (years): treatment group (62.7 ± 11.3); control group (64.1 ± 10.
8)
• Sex (M/F): treatment group (31/9); control group (31/6)
• Exclusion criteria: NS
Interventions Treatment group
• Simvastatin
• Dose, duration, frequency, administration: 20 mg/d, 4 weeks pre-operatively
Control group
• Proceeded directly to surgery
Outcomes • Number with AKI: serum urea ≥ 9 mmol/L and SCr ≥ 125 µmol/L
• Mortality
Notes • Grant from Merck Sharp and Dohme-Chibret SA (Pharmaceutical companies
producing the drug)
Risk of bias
Bias Authors’ judgement Support for judgement
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Christenson 1999 (Continued)
Random sequence generation (selection
bias)
Unclear risk Information not provided
Allocation concealment (selection bias) Unclear risk Information not provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “two independent surgeons who
were both unaware of the patients group
identity, performed all operations”
Comment: no other comment is made re-
garding blinding of participants, use of
placebo or methods of blinding the sur-
geons. Despite this, outcome measures
were objective, and therefore low risk of
bias is assigned
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No information was provided
Comment: Low risk of bias is assigned sec-
ondary to objective outcome measures un-
likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patient dropouts described
Selective reporting (reporting bias) High risk No information provided
Comment: No mention of adverse events
which would be expected in such a drug
study. As this is an expected outcome, this
is assigned high risk of bias
Other bias High risk Pharmaceutical company-sponsored study
Mannacio 2008
Methods • Study design: parallel double blinded, placebo controlled RCT
• Study duration: January 2005 to January 2007
Participants • Setting: inpatient, single centre
• Country: Italy
• Relevant health status: patients scheduled to undergo coronary artery bypass graft
surgery
◦ Hypertension: treatment group (25); control group (21)
• Number: treatment group (100); control group (100)
• Mean age ± SD (years): Treatment group (61.3 ± 9.2); control group (59.3 ± 8.4)
• Sex (M/F): treatment group (75/25); control group (70/30)
• Exclusion criteria: emergency cardiac surgery; associated cardiac surgery; acute MI
(< 3 months); poor cardiac function, as indicated by an ejection fraction < 35%;
undergoing surgical intervention for single- or quadruple-vessel disease, patients with
diffuse distal lesions of the left anterior descending coronary artery, a dominant right
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Mannacio 2008 (Continued)
coronary artery, and/or a dominant circumflex artery; Increase in creatine kinase-MB
mass, troponin I, or myoglobin values before surgery; high-sensitivity C-reactive
protein levels > 5 mg/L; moderate kidney failure (CrCl > 2.0 mL/min); active liver
disease or increased liver enzyme levels; type 1 and type 2 DM; contraindications to
statin treatments (history of liver or muscle disease); previous recent (60 days) therapy
with steroidal or NSAIDs; and previous recent (30 days) treatment with any kind of
statins; patients who could not suspend therapy for at least 30 days before the planned
surgery
Interventions Treatment group
• Rosuvastatin
• Dose, duration, frequency, administration: 20 mg/d; 7 days before surgery
Control group
• Placebo
• Dose, duration, frequency, administration: not reported
Outcomes • Number with AKI: “postoperative renal failure” defined as an increase in SCr > 2.
5 mg/dL (221 µmol/L)
Notes • Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “selection of patients for placebo or RSV
treatment was obtained on admission by
means of a computer generated algorithm”
Allocation concealment (selection bias) Low risk “randomisation was fully blinded without
any account of clinical or demographic fea-
tures”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of placebo for participant blinding,
personnel blinding and other methods of
concealment not described. However, this
was deemed low risk because it was unlikely
to influence the objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No explicit description of blinding, but
these were objective, and therefore deemed
to be low risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No mention of patient dropout; flow di-
agram not provided. However, given the
short follow-up period, there were poten-
tially no dropouts
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Mannacio 2008 (Continued)
Selective reporting (reporting bias) High risk Mortality was inadequately reported and
there was no mention of adverse events
Other bias Unclear risk Funding not reported; no other bias was
noted in this study
Prowle 2012
Methods • Study design: pilot, double-blinded RCT
• Study duration: February 2007 to August 2009
Participants • Setting: Single centre, inpatient
• Country: Australia
• Relevant health status: Informed consent for elective cardiac surgery with planned
cardiopulmonary bypass with ≥ 1 risk factors for postoperative kidney dysfunction (age
> 70, CHF (NYHA class 3 or 4), LVF < 35%, insulin dependent DM; prior cardiac
surgery, valvular surgery ± coronary artery bypass, pre-operative SCr > 106.1 µmol/L
◦ Baseline CKD, eGFR < 60 mL/min: treatment group (28%); control group
(36%)
◦ DM, insulin required: treatment group (12%); control group (4%)
◦ Hypertension: treatment group (78%); control group (78%)
◦ Chronic statin use: treatment group (70%); control group (70%)
◦ Emergency surgery: treatment group (2); control group (3)
• Number: treatment group (50); control group (50)
• Mean age ± SD (years): treatment group (69.0 ± 11.1); control group (67.3 ± 10.
8)
• Sex (M%): treatment group (66%); control group (74%)
• Exclusion criteria: emergent cardiac surgery, cardiac transplant or insertion of
device, planned off-pump cardiac surgery; hypersensitivity, allergy or known
intolerance to statins; premorbid ESKD or kidney transplant recipient; pre-operative
AKI, defined as an increase in SCr ≥ 88.4 µmol/L from pre- admission to surgery;
active liver disease or cirrhosis; pre-operative unexplained elevation of serum
transaminases; enrolled in a conflicting study; < 18 y; pregnancy
Interventions Treatment group
• Atorvastatin
• Dose, duration, administration, frequency: 40 mg/d on the day of operation (pre-
op) and for another 3 days post-op. Wash out of statin for chronic users of 24 hours
prior to surgery
Control group
• Placebo
• Dose, duration, administration, frequency: identical preparation to study drug
Outcomes • Number with AKI: SCr criteria of RIFLE consensus classification (RIFLE R, I or
F)
• Number requiring RRT
• Hospital mortality
• Adverse events: safety outcomes
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Prowle 2012 (Continued)
• SCr (µmol/L): SCr concentration daily for first 5 post-op days - reported change
in SCr from pre-op baseline to post-op peak
Notes • This study was partly funded by a grant from the Australian and New Zealand
College of Anaesthetists and by the Austin Hospital Anaesthesia and Intensive Care
Trust Fund, both federal non-profit foundations
• Perioperative SCr data was provided by authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The hospital pharmacy clinical trials coor-
dinator used a Microsoft Excel-based ran-
dom number generator to create the ran-
domisation list using a permuted block
strategy with blocks of 10”
Allocation concealment (selection bias) Low risk “Allocation concealment to patients, anaes-
thetists, cardiac surgeons, intensive care
specialists, bedside nurses and investigators
was ensured by central randomization”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Atorvastatin or placebo medication was
prepared in capsules of identical appear-
ance”; “the study drug or placebo was ad-
ministered orally in the pre-operative area
by a study investigator”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Treatment allocation was only revealed af-
ter data analysis had been performed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flowdiagram: 8 cases (2 emergency, 1with-
drew consent, 1 study drug stopped, 1 no
CPB), 7 controls (3 emergency, 3 study
drug stopped, 1 no CPB)
Given that the spread of patient loss was
even across both groups this was felt to rep-
resent low risk of bias. Furthermore, data
were analysed on ITT basis, followed by PP
basis
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk No other bias was identified in this study
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Spadaccio 2010
Methods • Study design: parallel RCT
• Study duration: September 2007 to March 2009
Participants • Setting: single centre, inpatient
• Country: Italy
• Relevant health status: elective CABG surgery
◦ Baseline CKD: not reported
◦ Hypertension: treatment group 13 (52%); control group 12 (48%)
◦ Chronic statin use: treatment group (0); control group (0)
◦ Emergency surgery: treatment group (0); control group (0)
• Number: treatment group (25); control group (25)
• Mean age ± SD (years): treatment group (65.9 ± 7.9); control group (64.8 ± 7.4)
• Sex (M/F): treatment group (13/12); control group (14/11)
• Exclusion criteria: DM; kidney or liver impairment; CHF; active inflammatory or
immunomodulatory diseases; history of MI < 6 months previously; pregnant women;
on ACEi
Interventions Treatment group
• Atorvastatin
• Dose, duration, administration, frequency: 20 mg/d 3 weeks before surgery
Control group
• Placebo
• Dose, duration, administration, frequency: not reported
Outcomes • Number with AKI (not defined)
• Mortality rate
• Adverse events: stroke, MI, sepsis, shock, ventilatory insufficiency, ventilation
more than 24h, revision for bleeding, post-op bleeding, atrial fibrillation, need for
inotropic support, need for blood transfusion
Notes • Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It was stated that recruited patients were
“randomised” but no details of randomisa-
tion method are provided
Allocation concealment (selection bias) Unclear risk No methods of allocation concealment
mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both patients and physicians were blinded
to the assignment group.”
Blinding methods not described; use of
placebo not described. However, this was
unlikely to influence outcomes
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Spadaccio 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Although reporting was suboptimal, it was
unlikely to affect objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data
Selective reporting (reporting bias) High risk Nomention of adverse events which would
be expected in such a drug study
Other bias Unclear risk Funding not reported; no other bias was
noted in this study
Tamayo 2009
Methods • Study design: parallel RCT
• Study duration: not reported
Participants • Setting: single centre
• Country: Spain
• Relevant health status: scheduled for elective CABG
◦ Baseline CKD (reported as SCr): treatment group (1) control group (1)
◦ Diabetics: treatment group (6); control group (9)
◦ Hypertension: treatment group (5); control group (11)
◦ Chronic statin use: not reported
• Number: treatment group (22); control group (22)
• Mean age ± SD (years): treatment group 67.7 ± 7.3); control group (68.0 ± 6.9)
• Sex (M/F): treatment group (17/5); control group (18/4)
• Exclusion criteria: kidney or hepatic impairment; congestive heart failure; severely
impaired LVEF (< 40%); active inflammatory disease, history of MI < 6 months prior,
preoperative steroid use
Interventions Treatment group
• Simvastatin
• Dose, duration, administration, frequency: 20 mg/d, for 3 weeks prior to surgery
Control group
• Not reported
• Dose, duration, administration, frequency: not reported
Outcomes • Mortality
• SCr (mg/dL)
Notes • Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Tamayo 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “except for perfusionists, clinical
team was blinded to the randomisation”
Comment: it is unclear why the perfusion-
ists were unblinded, and how the blind-
ing of other members of the team occurred
as no placebo is mentioned. However this
is unlikely to influence the objective out-
comes, therefore is deemed low risk
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No information is provided
Comment: despite lack of information, this
is deemed low risk as it is unlikely to influ-
ence the objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop outs and no missing data were
reported for this study
Selective reporting (reporting bias) High risk No information provided
Comment: There is no mention of adverse
events which would be expected in such a
drug study, therefore this is deemed high
risk
Other bias Low risk Funding not reported; no other bias was
noted in this study
ACEi - angiotensin-converting enzyme inhibitors; AKI - acute kidney injury; CABG - coronary artery bypass grafting; CHF - chronic
heart failure; CKD - chronic kidney disease; CPB - cardiopulmonary bypass; CrCl - creatinine clearance; DM - diabetes mellitus;
eGFR - estimated glomerular filtration rate; ESKD - end-stage kidney disease; ITT - intention to treat; LVEF - left ventricular ejection
fraction; MI - myocardial infarction; NSAID - nonsteroidal anti-inflammatory drug; PP - per protocol; RRT - renal replacement
therapy; SCr - serum creatinine
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Acikel 2010 No procedure of interest
Almeida 2010 No procedure of interest
Antoniades 2010 No outcome of interest
Antoniades 2010a No outcome of interest
ARMYDA-CIN 2011 No procedure of interest
Barbir 1994 No outcome of interest
Berkan 2009 No outcome of interest
Caorsi 2008 No outcome of interest
Chello 2003 No outcome of interest
Chello 2005 No outcome of interest
Chello 2007 No outcome of interest
Chen 2009a No procedure of interest
Cobbaert 1992 No outcome of interest
Coccia 2007 No outcome of interest
Dotani 2003 No outcome of interest
Dunkelgrun 2009 No procedure of interest
Durazzo 2004 No procedure of interest
Faulkner 2000 No procedure of interest
Flaker 1999 No procedure of interest
FLARE Study 1999 No procedure of interest
Florens 2001 No outcome of interest
Foley 1994 No procedure of interest
Han 2014 No procedure of interest
Ji 2009 No outcome of interest
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(Continued)
Kesteloot 1992 No outcome of interest
Kourliouros 2011 No outcome of interest
Krivoy 2008 No outcome of interest
Li 2012a No procedure of interest
LIPS Study 2002 No procedure of interest
Lotfi 2008 No procedure of interest
Ludman 2010 No placebo arm
Morawietz 2006 No outcome of interest
Nakamura 2006b No outcome of interest
Ozhan 2010 No procedure of interest
Post-CABG Trial 1997 Statin treatment used in both arms
PRATO-ACS Study 2014 No procedure of interest
PROMISS Study 2008 No procedure of interest
Qian 2008 No outcome of interest
Radaelli 2007 Dual agents used (ACEi + statin), no placebo arm
RAP Study 2010 Data extracted from RCT, not randomised to statin versus placebo
Riahi 2006 No outcome of interest
Sasmazel 2010 No outcome of interest
Schanzer 2008 Not procedure of interest
Schouten 2009 Not procedure of interest
Song 2008 No outcome of interest
STATIN-STEMI Study 2010 No procedure of interest
Su 2011 No procedure of interest
Sun 2009a No outcome of interest
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(Continued)
Tetik 2010 Statin treatment given in both arms of study
Toso 2010 No procedure of interest
Xinwei 2009 No procedure of interest
Zhou 2009 No procedure of interest
Zhou 2010 No outcome of interest
ACEi - angiotensin-converting enzyme inhibitor; RCT - randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT01547455
Trial name or title Anti-inflammatory and renoprotective effect of pretreatment loading dose atorvastatin in CABG
Methods Randomised double blind parallel study
Participants Adult patients >18 y old having elective CABG with cardiopulmonary bypass
Interventions • Participants to take 80 mg atorvastatin orally 12 h prior to surgery with another 40 mg 4 h prior
• Placebo controlled comparison arm
Outcomes Primary outcome measures
• Acute kidney injury [Time frame: 72 hours postoperative]: proportion developing AKI using AKIN
criteria (stage 1,2,3)
• SCr to 72 hours postoperative
• CrCl
Secondary outcome measures
• Change in inflammatory biomarkers (IL-6, IL-10, TNF-a, hsCRP) to 48 hours postoperatively, need
for RRT, liver dysfunction (to 2 weeks postoperatively, defined as transaminase rise 3 x ULN), death, length
of stay in ICU
Starting date March 2012
Contact information Shan Zhou MD, +86 15201506389, zhoushan.whu@live.cn
Notes
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STATIN AKI 2011
Trial name or title Short-term atorvastatin’s effect on acute kidney injury following cardiac surgery
Methods RCT
Participants Adults > 18 y undergoing cardiac surgery
Interventions • Statin naive patients to receive 80 mg atorvastatin 1 day prior to operation and 40 mg daily
postoperatively until hospital discharge, versus placebo
• Patients already on statin treatment to receive loading of 80 mg atorvastatin day prior to operation and
40 mg postoperative day 1 versus placebo
Outcomes Primary outcomes
• AKI (at randomisation, anaesthetic and postoperative days 1,2 and 3)
• Delirium at randomisation, daily in ICU, up to 6 months)
Secondary outcomes
• Need for RRT, urine markers of AKI, plasma markers of inflammation, liver enzymes, stroke, death,
plasma and urine markers of oxidative stress and mitochondrial function
Starting date July 2009
Contact information Frederic T. Billings, Vanderbilt University Medical Centre: frederic.t.billings@vanderbilt.edu
Notes Estimated completion July 2015
ACEi - angiotensin-converting enzyme inhibitor; AKI - acute kidney injury; CABG - coronary artery bypass grafting; CrCl - creatinine
clearance; ICU - intensive care unit; RCT - randomised controlled trial; RRT - renal replacement therapy; SCr - serum creatinine
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D A T A A N D A N A L Y S E S
Comparison 1. Statins versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Acute kidney injury 5 467 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.46, 1.28]
1.1 Atorvastatin 3 190 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.46, 1.49]
1.2 Simvastatin 1 77 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.10, 1.21]
1.3 Rosuvastatin 1 200 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.32, 28.35]
2 Serum creatinine: 24 h
postoperatively
2 195 Mean Difference (IV, Random, 95% CI) -21.25 [-31.09, -11.
41]
2.1 Simvastatin 2 195 Mean Difference (IV, Random, 95% CI) -21.25 [-31.09, -11.
41]
3 Serum creatinine: 48 h
postoperatively
2 195 Mean Difference (IV, Random, 95% CI) -20.97 [-34.58, -7.
35]
3.1 Simvastatin 2 195 Mean Difference (IV, Random, 95% CI) -20.97 [-34.58, -7.
35]
4 Mortality 6 458 Risk Ratio (M-H, Random, 95% CI) 3.86 [0.43, 34.40]
4.1 Atorvastatin 3 190 Risk Ratio (M-H, Random, 95% CI) 5.00 [0.25, 101.58]
4.2 Simvastatin 3 268 Risk Ratio (M-H, Random, 95% CI) 2.88 [0.12, 69.70]
5 Renal replacement therapy 2 251 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.23, 2.81]
5.1 Atorvastatin 1 100 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.23, 2.81]
5.2 Simvastatin 1 151 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Adverse events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 ALT x 3 ULN 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Creatinine kinase > 5000
IU/L
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Study drug cessation 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Statins versus placebo/no treatment, Outcome 1 Acute kidney injury.
Review: HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
Comparison: 1 Statins versus placebo/no treatment
Outcome: 1 Acute kidney injury
Study or subgroup Statin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Atorvastatin
Chello 2006 1/20 1/20 3.7 % 1.00 [ 0.07, 14.90 ]
Prowle 2012 13/50 16/50 70.2 % 0.81 [ 0.44, 1.51 ]
Spadaccio 2010 1/25 1/25 3.6 % 1.00 [ 0.07, 15.12 ]
Subtotal (95% CI) 95 95 77.5 % 0.83 [ 0.46, 1.49 ]
Total events: 15 (Statin), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Simvastatin
Christenson 1999 3/40 8/37 17.2 % 0.35 [ 0.10, 1.21 ]
Subtotal (95% CI) 40 37 17.2 % 0.35 [ 0.10, 1.21 ]
Total events: 3 (Statin), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
3 Rosuvastatin
Mannacio 2008 3/100 1/100 5.3 % 3.00 [ 0.32, 28.35 ]
Subtotal (95% CI) 100 100 5.3 % 3.00 [ 0.32, 28.35 ]
Total events: 3 (Statin), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 235 232 100.0 % 0.76 [ 0.46, 1.28 ]
Total events: 21 (Statin), 27 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.07, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Chi2 = 3.03, df = 2 (P = 0.22), I2 =34%
0.01 0.1 1 10 100
Favours statin Favours control
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Analysis 1.2. Comparison 1 Statins versus placebo/no treatment, Outcome 2 Serum creatinine: 24 h
postoperatively.
Review: HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
Comparison: 1 Statins versus placebo/no treatment
Outcome: 2 Serum creatinine: 24 h postoperatively
Study or subgroup Statin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Simvastatin
Almansob 2012 77 77.6 (23.8) 74 100.9 (40.4) 85.7 % -23.30 [ -33.93, -12.67 ]
Tamayo 2009 22 106 (44) 22 115 (44) 14.3 % -9.00 [ -35.00, 17.00 ]
Total (95% CI) 99 96 100.0 % -21.25 [ -31.09, -11.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 4.23 (P = 0.000023)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
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Analysis 1.3. Comparison 1 Statins versus placebo/no treatment, Outcome 3 Serum creatinine: 48 h
postoperatively.
Review: HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
Comparison: 1 Statins versus placebo/no treatment
Outcome: 3 Serum creatinine: 48 h postoperatively
Study or subgroup Statin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Simvastatin
Almansob 2012 77 66 (25) 74 91 (55) 74.8 % -25.00 [ -38.72, -11.28 ]
Tamayo 2009 22 106 (44) 22 115 (44) 25.2 % -9.00 [ -35.00, 17.00 ]
Total (95% CI) 99 96 100.0 % -20.97 [ -34.58, -7.35 ]
Heterogeneity: Tau2 = 15.50; Chi2 = 1.14, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours statin Favours placebo
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Analysis 1.4. Comparison 1 Statins versus placebo/no treatment, Outcome 4 Mortality.
Review: HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
Comparison: 1 Statins versus placebo/no treatment
Outcome: 4 Mortality
Study or subgroup Statin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Atorvastatin
Chello 2006 0/20 0/20 Not estimable
Prowle 2012 2/50 0/50 52.8 % 5.00 [ 0.25, 101.58 ]
Spadaccio 2010 0/25 0/25 Not estimable
Subtotal (95% CI) 95 95 52.8 % 5.00 [ 0.25, 101.58 ]
Total events: 2 (Statin), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Simvastatin
Almansob 2012 1/77 0/74 47.2 % 2.88 [ 0.12, 69.70 ]
Christenson 1999 0/40 0/37 Not estimable
Tamayo 2009 0/20 0/20 Not estimable
Subtotal (95% CI) 137 131 47.2 % 2.88 [ 0.12, 69.70 ]
Total events: 1 (Statin), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Total (95% CI) 232 226 100.0 % 3.86 [ 0.43, 34.40 ]
Total events: 3 (Statin), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
0.005 0.1 1 10 200
Favours statin Favours control
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Analysis 1.5. Comparison 1 Statins versus placebo/no treatment, Outcome 5 Renal replacement therapy.
Review: HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
Comparison: 1 Statins versus placebo/no treatment
Outcome: 5 Renal replacement therapy
Study or subgroup Statin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Atorvastatin
Prowle 2012 4/50 5/50 100.0 % 0.80 [ 0.23, 2.81 ]
Subtotal (95% CI) 50 50 100.0 % 0.80 [ 0.23, 2.81 ]
Total events: 4 (Statin), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
2 Simvastatin
Almansob 2012 0/77 0/74 Not estimable
Subtotal (95% CI) 77 74 Not estimable
Total events: 0 (Statin), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 127 124 100.0 % 0.80 [ 0.23, 2.81 ]
Total events: 4 (Statin), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.6. Comparison 1 Statins versus placebo/no treatment, Outcome 6 Adverse events.
Review: HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
Comparison: 1 Statins versus placebo/no treatment
Outcome: 6 Adverse events
Study or subgroup Statin Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALT x 3 ULN
Prowle 2012 1/50 4/50 0.25 [ 0.03, 2.16 ]
2 Creatinine kinase > 5000 IU/L
Prowle 2012 4/50 1/50 4.00 [ 0.46, 34.54 ]
3 Study drug cessation
Prowle 2012 4/50 3/50 1.33 [ 0.31, 5.65 ]
0.01 0.1 1 10 100
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor: [Coronary Artery Bypass] explode all trees
2. bypass*:ti,ab,kw in Trials
3. coronary artery bypass*:ti,ab,kw in Trials
4. coronary bypass grafting surgery:ti,ab,kw in Trials
5. (valve* or cardiac) and surger*:ti,ab,kw in Trials
6. CABG:ti,ab,kw in Trials
7. MeSH descriptor: [Thoracic Surgery] this term only
8. cardiac surg*:ti,ab,kw in Trials
9. valve replacement*:ti,ab,kw in Trials
10. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 in Trials
11. MeSH descriptor: [Hydroxymethylglutaryl-CoA Reductase Inhibitors] explode all trees
12. statin*:ti,ab,kw in Trials
13. “HMG-CoA”:ti,ab,kw in Trials
14. hydroxymethylglutaryl-coa reductase inhibitor*:ti,ab,kw in Trials
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(Continued)
15. simvastatin:ti,ab,kw OR fluvastatin:ti,ab,kw OR cervistatin:ti,ab,kw OR lovastatin:ti,ab,kw OR pravastatin:ti,
ab,kw in Trials
16. atorvastatin:ti,ab,kw OR rosuvastatin:ti,ab,kw OR Lipitor:ti,ab,kw OR Baycol:ti,ab,kw OR Lescol:ti,ab,kw in
Trials
17. (Mevcor):ti,ab,kw or (Altocar):ti,ab,kw or (Pravacol):ti,ab,kw or (Lipostat):ti,ab,kw or (Zocor):ti,ab,kw or
(Crestor):ti,ab,kw in Trials
18. #11 or #12 or #13 or #14 or #15 or #16 or #17 in Trials
19. MeSH descriptor: [Acute kidney Injury] explode all trees
20. acute kidney failure*:ti,ab,kw OR acute renal failure*:ti,ab,kw in Trials
21. acute kidney injur*:ti,ab,kw OR acute renal injur*:ti,ab,kw in Trials
22. acute kidney insufficie*:ti,ab,kw OR acute renal insufficie*:ti,ab,kw in Trials
23. acute tubular necrosis:ti,ab,kw in Trials
24. ARF or AKF or ATN:ti,ab,kw in Trials
25. #19 or #20 or #21 or #22 or #23 or #24 in Trials
26. #10 and #18 in Trials
27. #10 and #25 in Trials
28. #18 and #25 in Trials
29. #26 or #27 or #28 in Trials
MEDLINE 1. exp Coronary Artery Bypass/
2. bypass.tw.
3. coronary artery bypass$.tw.
4. coronary bypass grafting surgery.tw.
5. ((valve$ or cardiac) and surgery).tw.
6. CABG.tw.
7. Thoracic Surgery/
8. cardiac surgery.tw.
9. valve replacement$.tw.
10. or/1-9
11. exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/
12. statin$.tw. 13. “HMG-CoA”.tw.
14. hydroxymethylglutaryl-coa reductase inhibitor$.tw.
15. simvastatin.tw.
16. fluvastatin.tw.
17. cervistatin.tw.
18. lovastatin.tw.
19. pravastatin.tw.
20. atorvastatin.tw.
21. rosuvastatin.tw.
22. Lipitor.tw.
23. Baycol.tw.
24. Lescol.tw.
25. Mevcor.tw.
26. Altocar.tw.
27. Pravacol.tw.
28. Lipostat.tw.
29. Zocor.tw.
30. Crestor.tw.
31. or/11-30
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(Continued)
32. exp Acute Kidney Injury/
33. (acute kidney failure or acute renal failure).tw.
34. (acute kidney injur$ or acute renal injur$).tw.
35. (acute kidney insufficie$ or acute renal insufficie$).tw
36. acute tubular necrosis.tw.
37. (ARF or AKF or ATN).tw.
38. or/32-37
39. and/10,31
40. and/10,38
41. and/31,38
42. or/39-41
EMBASE 1. exp coronary artery surgery/
2. thorax surgery/
3. bypass.tw.
4. coronary artery bypass$.tw.
5. coronary bypass grafting surgery.tw.
6. ((valve$ or cardiac) and surgery).tw.
7. CABG.tw.
8. cardiac surgery.tw.
9. valve replacement$.tw.
10. or/1-9
11. exp hydroxymethylglutaryl coenzyme A reductase inhibitor/
12. statin$.tw.
13. “HMG-CoA”.tw.
14. hydroxymethylglutaryl-coa reductase inhibitor$.tw.
15. (simvastatin or fluvastatin or cervistatin or lovastatin or pravastatin or atorvastatin or rosuvastatin).tw
16. (Lipitor or Baycol or Lescol or Mevcor or Altocar or Pravacol or Lipostat or Zocor or Crestor).tw
17. or/11-16
18. exp acute kidney failure/
19. (acute kidney failure or acute renal failure).tw.
20. (acute kidney injur$ or acute renal injur$).tw.
21. (acute kidney insufficie$ or acute renal insufficie$).tw
22. acute tubular necrosis.tw.
23. (ARF or AKF or ATN).tw.
24. or/18-23
25. and/10,17
26. and/10,24
27. and/17,24
28. or/25-27
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Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
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(Continued)
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
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(Continued)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Although our published protocol specified conversion of raw SCr data to classify patients according to AKIN criteria, this was not
possible secondary to insufficient data being available from included studies. As such, patients were assessed as having developed AKI
as specified by the study authors.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Kidney Injury [∗prevention & control; therapy]; Atorvastatin Calcium; Cardiac Surgical Procedures; Cardiopulmonary Bypass
[∗adverse effects]; Coronary Artery Bypass [∗adverse effects]; Creatinine [blood]; Fluorobenzenes [therapeutic use]; Heptanoic Acids
[∗therapeutic use]; Hydroxymethylglutaryl-CoA Reductase Inhibitors [∗therapeutic use]; Length of Stay; Pyrimidines [therapeutic use];
Pyrroles [∗therapeutic use]; Randomized Controlled Trials as Topic; Renal Replacement Therapy; Rosuvastatin Calcium; Simvastatin
[therapeutic use]; Sulfonamides [therapeutic use]
MeSH check words
Adult; Humans
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